Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun 28;13(1):104.
doi: 10.1186/s13023-018-0851-1.

Using a meta-narrative literature review and focus groups with key stakeholders to identify perceived challenges and solutions for generating robust evidence on the effectiveness of treatments for rare diseases

Affiliations
Review

Using a meta-narrative literature review and focus groups with key stakeholders to identify perceived challenges and solutions for generating robust evidence on the effectiveness of treatments for rare diseases

Kylie Tingley et al. Orphanet J Rare Dis. .

Abstract

Introduction: For many rare diseases, strong analytic study designs for evaluating the efficacy and effectiveness of interventions are challenging to implement because of small, geographically dispersed patient populations and underlying clinical heterogeneity. The objective of this study was to integrate perspectives from published literature and key rare disease stakeholders to better understand the perceived challenges and proposed methodological approaches to research on clinical interventions for rare diseases.

Methods: We used a meta-narrative literature review and focus group interviews with key rare disease stakeholders to better understand the perceived challenges in generating and synthesizing treatment effectiveness evidence, and to describe various research methods for mitigating these identified challenges. Data from both components of this study were synthesized narratively according to research paradigms that emerged from our data.

Results: Results from our meta-narrative literature review and focus group interviews revealed three fundamental challenges in generating robust treatment effectiveness evidence for rare diseases: i) limitations in recruiting a sufficient sample size to achieve planned statistical power; ii) inability to account for clinical heterogeneity and assess treatment effects across a clinical spectrum; and iii) reliance on short-term, surrogate outcomes whose clinical relevance is often unclear. We mapped these challenges and associated solutions to three interrelated research paradigms: i) explanatory evidence generation; ii) comparative effectiveness/pragmatic evidence generation; and iii) patient-oriented evidence generation. Within each research paradigm, numerous criticisms and potential solutions have been described with respect to overcoming these challenges from a research study design perspective.

Conclusions: Over time, discussions about clinical research for interventions for rare diseases have moved beyond methodological approaches to overcome challenges related to explanatory evidence generation, with increased recognition of the importance of pragmatic and patient-oriented evidence. Future directions for our work include developing a framework to expand current evidence synthesis practices to take into consideration many of the concepts discussed in this paper.

Keywords: Comparative effectiveness; Evidence generation; Evidence synthesis; Patient-oriented outcomes; Rare diseases; Research methods.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Ethics approval for this study was obtained from the Children’s Hospital of Eastern Ontario Research Ethics Board, the Ottawa Health Science Research Network Research Ethics Board, and the University of Ottawa Health Sciences and Sciences Research Ethics Board. Informed consent was received from all participants in this study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
PRISMA flow diagram outlining results from search and screening process. (Adapted from: Liberati et al. 2009) [29]
Fig. 2
Fig. 2
Research paradigms discussed by year of publication (note: research paradigms are not mutually exclusive)

References

    1. Revicki DA, Frank L. Pharmacoeconomic evaluation in the real world. PharmacoEconomics. 1999;15:423–34. - PubMed
    1. Griggs RC, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J, et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab. 2009;96:20–26. doi: 10.1016/j.ymgme.2008.10.003. - DOI - PMC - PubMed
    1. Wästfelt M, Fadeel B. Henter J-I. A journey of hope: lessons learned from studies on rare diseases and orphan drugs. J Intern Med. 2006;260:1–10. doi: 10.1111/j.1365-2796.2006.01666.x. - DOI - PubMed
    1. Augustine EF, Adams HR, Mink JW. Clinical trials in rare disease: challenges and opportunities. J Child Neurol. 2013;28:1142–1150. doi: 10.1177/0883073813495959. - DOI - PMC - PubMed
    1. Kaptchuk TJ. The double-blind, randomized, placebo-controlled trial: Gold standard or golden calf? J Clin Epidemiol. 2001;54:541–549. doi: 10.1016/S0895-4356(00)00347-4. - DOI - PubMed

Publication types

Grants and funding